The Greater Cannabis Company, Inc. (GCAN)

OTCMKTS: GCAN · Delayed Price · USD
0.0006
0.00 (0.00%)
Mar 28, 2024, 1:44 PM EDT - Market closed

Company Description

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics.

It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body.

The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders.

The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.

The Greater Cannabis Company, Inc.
Country MD
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1
CEO Aitan Zacharin

Contact Details

Address:
15 Walker Ave, Suite 101
Baltimore, Maryland 21208
United States
Phone (443) 738-4051
Website gcanrx.com

Stock Details

Ticker Symbol GCAN
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001695473
CUSIP Number 391657103
ISIN Number US3916571033
Employer ID 30-0842570
SIC Code 2834

Key Executives

Name Position
Aitan Zacharin Chairman, President, Chief Executive Officer, Acting Chief Financial Officer and Treasurer
Motti Stenge Chief Operating Officer
Dr. Adi Aran M.D. Chief Scientific Advisor

Latest SEC Filings

Date Type Title
Feb 26, 2024 PRER14C Filing
Nov 13, 2023 10-Q Quarterly Report
Aug 16, 2023 8-K Current Report
Aug 14, 2023 10-Q Quarterly Report
May 12, 2023 10-Q Quarterly Report
Apr 13, 2023 10-K Annual Report
Apr 3, 2023 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Jan 26, 2023 8-K Current Report
Nov 21, 2022 PRE 14A Other preliminary proxy statements
Nov 14, 2022 10-Q Quarterly Report